Clinical Challenges: Nuclear Medicine and Neuroendocrine Tumors

Peptide receptor radionuclide therapy for advanced neuroendocrine tumors that affect pancreas, GI tract by Mike Bassett, Contributing Writer, MedPage Today April 30, 2020 MedpageToday email article
The most significant recent development in the treatment of patients with metastasized or inoperable neuroendocrine tumors (NETs) has been the FDA approval of peptide receptor radionuclide therapy (PRRT). The treatment has a history dating back to the early 1990s.

Read the source article at Medical News and Free Online CME

Rose Duesterwald

Rose Duesterwald

Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia four years ago. He was treated with a methylating agent While he was being treated with a hypomethylating agent, Rose researched investigational drugs being developed to treat relapsed/refractory AML.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email
Close Menu